Latest Information

Aveo Announces Kidney Cancer Drug Tivozanib Meets Late-Stage Goal

January 4, 2012
“The drug helped patients with advanced renal cell carcinoma live for 11.9 months without their disease progressing in a late-stage study, compared with 9.1 months for those on Nexavar [sorafenib].”

December 28, 2011
Reuters (12/29, Pittman) reports a study in the American Journal of Clinical Nutrition suggesting that people who eat high amounts of red, grilled, or barbequed meat may be at higher risk of kidney cancer. In a study of 500,000 US adults, it was found that eating the most red meat was linked with papillary cancers, but not clear-cell kidney cancers. Participants who ate high amounts of well-done grilled and barbecued meat likewise had an increased risk of kidney cancer. Researchers said the reason for the association is unclear and emphasized that the data do not prove causation.

ICUD/EAU consensus statement on mRCC

December 8, 2011
The International Consultation on Urological Diseases and the European Association of Urology have published a consensus statement on the management of mRCC.

Votrient (pazopanib) Approved by Health Canada for the Treatment of Renal Cell Carcinoma

Wednesday, June 16, 2010
Original Article

Health Canada has approved Votrient (pazopanib) for metastatic renal cell carcinoma. According to the Health Canada announcement, the Notice of Compliance (NOC) states that pazopanib has been approved for first-line treatment of metastatic clear cell renal cell carcinoma, or second-line treatment following cytokine therapy (such as Inteferon or Interleukin).

Submissions will be made to the Joint Oncology Drug Review (JODR) and to the Conseil de medicament (Quebec) for reimbursement recommendations. Based upon past experiences, it is understood that this process, including provincial decisions on funding, may take up to one year after the submission is made to Joint Oncology Drug Review. Further information about programs for accessing pazopanib will be available on www.kidneycancercanada.org when known. In the meantime, patients with private drug insurance may be able to access pazopanib beginning later this summer when supplies are available in Canada.

If you have any questions about Votrient/pazopanib for mrcc, please ask your oncologist.

Filed Under: Uncategorized